Home LiteratureArticle Details
PMID: 18332434 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons.

Liang WS, Reiman EM, Valla J, Dunckley T, Beach TG, Grover A, Niedzielko TL, Schneider LE, Mastroeni D, Caselli R, Kukull W, Morris JC, Hulette CM, Schmechel D, Rogers J, Stephan DA

Abstract

Alzheimer's disease (AD) is associated with regional reductions in fluorodeoxyglucose positron emission tomography (FDG PET) measurements of the cerebral metabolic rate for glucose, which may begin long before the onset of histopathological or clinical features, especially in carriers of a common AD susceptibility gene. Molecular evaluation of cells from metabolically affected brain regions could provide new information about the pathogenesis of AD and new targets at which to aim disease-slowing and prevention therapies. Data from a genome-wide transcriptomic study were used to compare the expression of 80 metabolically relevant nuclear genes from laser-capture microdissected non-tangle-bearing neurons from autopsy brains of AD cases and normal controls in posterior cingulate cortex, which is metabolically affected in the earliest stages; other brain regions metabolically affected in PET studies of AD or normal aging; and visual cortex, which is relatively spared. Compared with controls, AD cases had significantly lower expression of 70% of the nuclear genes encoding subunits of the mitochondrial electron transport chain in posterior cingulate cortex, 65% of those in the middle temporal gyrus, 61% of those in hippocampal CA1, 23% of those in entorhinal cortex, 16% of those in visual cortex, and 5% of those in the superior frontal gyrus. Western blots confirmed underexpression of those complex I-V subunits assessed at the protein level. Cerebral metabolic rate for glucose abnormalities in FDG PET studies of AD may be associated with reduced neuronal expression of nuclear genes encoding subunits of the mitochondrial electron transport chain.

MeSH Terms
Aged Alzheimer Disease/genetics,metabolism Brain/metabolism Energy Metabolism Female Gene Expression Regulation/genetics Humans Male Neurons/metabolism
Authors & Affiliations
16 authors, click to expand affiliations / ORCID
Liang Winnie S
Neurogenomics Division, Translational Genomics Research Institute, 445 North Fifth Street, Phoenix, AZ 85004, USA.
Reiman Eric M
Valla Jon
Dunckley Travis
Beach Thomas G
Grover Andrew
Niedzielko Tracey L
Schneider Lonnie E
Mastroeni Diego
Caselli Richard
Kukull Walter
Morris John C
Hulette Christine M
Schmechel Donald
Rogers Joseph
Stephan Dietrich A
References (53)
53 references, click to expand
  1. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.
    Neurology. 1991 Apr;41(4):479-86 PMID: 2011243
  2. Protein import into mitochondria.
    IUBMB Life. 2001 Sep-Nov;52(3-5):101-12 PMID: 11798021
  3. Regional cerebral function determined by FDG-PET in healthy volunteers: normal patterns and changes with age.
    J Nucl Med. 1995 Jul;36(7):1141-9 PMID: 7790936
  4. The metabolic topography of normal aging.
    J Cereb Blood Flow Metab. 1996 May;16(3):385-98 PMID: 8621743
  5. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications.
    Arch Neurol. 1992 Nov;49(11):1142-50 PMID: 1444881
  6. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease.
    Neurology. 1984 Jul;34(7):939-44 PMID: 6610841
  7. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease.
    Ann Neurol. 1997 Jul;42(1):85-94 PMID: 9225689
  8. The MIM complex mediates preprotein translocation across the mitochondrial inner membrane and couples it to the mt-Hsp70/ATP driving system.
    Cell. 1995 Jun 30;81(7):1085-93 PMID: 7600576
  9. Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia.
    Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):284-9 PMID: 14688411
  10. Decreased expression of nuclear and mitochondrial DNA-encoded genes of oxidative phosphorylation in association neocortex in Alzheimer disease.
    Brain Res Mol Brain Res. 1997 Feb;44(1):99-104 PMID: 9030703
  11. Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation.
    J Neurosci. 1997 Feb 1;17(3):1046-54 PMID: 8994059
  12. Greater metabolic rate decreases in hippocampal formation and proisocortex than in neocortex in Alzheimer's disease.
    Neuropsychobiology. 1998;37(1):10-9 PMID: 9438267
  13. Hippocampal formation glucose metabolism and volume losses in MCI and AD.
    Neurobiol Aging. 2001 Jul-Aug;22(4):529-39 PMID: 11445252
  14. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.
    Pharmacogenomics J. 2006 Jul-Aug;6(4):246-54 PMID: 16446752
  15. Neuropathological stageing of Alzheimer-related changes.
    Acta Neuropathol. 1991;82(4):239-59 PMID: 1759558
  16. Cellular bases of brain energy metabolism and their relevance to functional brain imaging: evidence for a prominent role of astrocytes.
    Cereb Cortex. 1996 Jan-Feb;6(1):50-61 PMID: 8670638
  17. Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain.
    Physiol Genomics. 2007 Feb 12;28(3):311-22 PMID: 17077275
  18. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory.
    J Neurosci. 2005 Aug 24;25(34):7709-17 PMID: 16120771
  19. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET).
    Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10966-71 PMID: 11526211
  20. Pattern of cerebral metabolic interactions in a subject with isolated amnesia at risk for Alzheimer's disease: a longitudinal evaluation.
    Dementia. 1993 Mar-Apr;4(2):94-101 PMID: 8358518
  21. Regional cerebral glucose metabolism in healthy volunteers determined by fluordeoxyglucose positron emission tomography: appearance and variance in the transaxial, coronal, and sagittal planes.
    Clin Nucl Med. 2000 Aug;25(8):596-602 PMID: 10944013
  22. The APOE-epsilon4 allele and the risk of Alzheimer disease among African Americans, whites, and Hispanics.
    JAMA. 1998 Mar 11;279(10):751-5 PMID: 9508150
  23. Volumetric analysis of the pre-frontal regions: findings in aging and schizophrenia.
    Psychiatry Res. 2001 Aug 25;107(2):61-73 PMID: 11530273
  24. Posterior cingulate cortex in Alzheimer's disease.
    Lancet. 1994 Sep 24;344(8926):895 PMID: 7916431
  25. Energy hypometabolism in posterior cingulate cortex of Alzheimer's patients: superficial laminar cytochrome oxidase associated with disease duration.
    J Neurosci. 2001 Jul 1;21(13):4923-30 PMID: 11425920
  26. Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat.
    Science. 1979 Aug 17;205(4407):723-5 PMID: 462184
  27. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.
    Science. 1993 Aug 13;261(5123):921-3 PMID: 8346443
  28. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.
    N Engl J Med. 1996 Mar 21;334(12):752-8 PMID: 8592548
  29. Protein translocation into mitochondria: the role of TIM complexes.
    Trends Cell Biol. 2000 Jan;10(1):25-31 PMID: 10603473
  30. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease.
    Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3334-9 PMID: 11248079
  31. Regional differences and metabolic changes in normal aging of the human brain: proton MR spectroscopic imaging study.
    AJNR Am J Neuroradiol. 2001 Jan;22(1):119-27 PMID: 11158897
  32. A default mode of brain function.
    Proc Natl Acad Sci U S A. 2001 Jan 16;98(2):676-82 PMID: 11209064
  33. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET.
    J Nucl Med. 1995 Jul;36(7):1238-48 PMID: 7790950
  34. Clinical deterioration in probable Alzheimer's disease correlates with progressive metabolic impairment of association areas.
    Dementia. 1994 Jan-Feb;5(1):36-41 PMID: 8156085
  35. 18Fluorodeoxyglucose positron emission tomography studies in presumed Alzheimer cases, including 13 serial scans.
    Can J Neurol Sci. 1990 Feb;17(1):1-11 PMID: 2311010
  36. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
    Pharmacogenomics J. 2007 Feb;7(1):10-28 PMID: 16770341
  37. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease.
    JAMA. 1995 Mar 22-29;273(12):942-7 PMID: 7884953
  38. Versatility of the mitochondrial protein import machinery.
    Nat Rev Mol Cell Biol. 2001 May;2(5):339-49 PMID: 11331908
  39. Hippocampal hypometabolism predicts cognitive decline from normal aging.
    Neurobiol Aging. 2008 May;29(5):676-92 PMID: 17222480
  40. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism.
    Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8299-302 PMID: 15932949
  41. The neural substrates of memory systems impairment in Alzheimer's disease. A PET study of resting brain glucose utilization.
    Brain. 1998 Apr;121 ( Pt 4):611-31 PMID: 9577389
  42. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease.
    Neurology. 2006 Aug 8;67(3):446-52 PMID: 16894106
  43. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects.
    Arch Neurol. 2000 Mar;57(3):339-44 PMID: 10714659
  44. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease.
    Neurology. 1998 Jun;50(6):1585-93 PMID: 9633698
  45. Gene expression correlates of neurofibrillary tangles in Alzheimer's disease.
    Neurobiol Aging. 2006 Oct;27(10):1359-71 PMID: 16242812
  46. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies.
    Am J Psychiatry. 2002 May;159(5):738-45 PMID: 11986126
  47. Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD.
    Neurology. 2004 Feb 24;62(4):591-600 PMID: 14981176
  48. Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer disease.
    Brain Res Mol Brain Res. 1994 Jul;24(1-4):336-40 PMID: 7968373
  49. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.
    Neurology. 1993 Aug;43(8):1467-72 PMID: 8350998
  50. Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set.
    Physiol Genomics. 2008 Apr 22;33(2):240-56 PMID: 18270320
  51. The role of biomarkers in clinical trials for Alzheimer disease.
    Alzheimer Dis Assoc Disord. 2006 Jan-Mar;20(1):6-15 PMID: 16493230
  52. Diminished glucose transport and phosphorylation in Alzheimer's disease determined by dynamic FDG-PET.
    J Nucl Med. 1996 Feb;37(2):201-8 PMID: 8667045
  53. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease.
    Proc Natl Acad Sci U S A. 2000 May 23;97(11):6037-42 PMID: 10811879
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
1091-6490
Published
2008-03-18
Epub
2008-00-10
Pages
4441-6
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC2393743
Subset
IM
Grants
NIA NIH HHS · P50 AG05681 · United States
NIA NIH HHS · P50 AG005128 · United States
NIA NIH HHS · P01 AG03991 · United States
NIA NIH HHS · K01 AG024079-03 · United States
NIA NIH HHS · P30 AG19610 · United States
NIA NIH HHS · P30 AG019610 · United States
NIA NIH HHS · R01 AG023193 · United States
NIA NIH HHS · 1-RO1-AG023193 · United States
NIA NIH HHS · K01 AG024079 · United States
NIA NIH HHS · U01AG016976 · United States
NIA NIH HHS · AG05128 · United States
NIA NIH HHS · U01 AG016976 · United States
NIA NIH HHS · P01 AG003991 · United States
NIA NIH HHS · P50 AG005681 · United States
NIA NIH HHS · K01AG024079 · United States
NIA NIH HHS · K01 AG024079-02 · United States
Databases
GEO
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com